170 related articles for article (PubMed ID: 38017133)
1. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα.
Yang P; Yang X; Wang D; Yang H; Li Z; Zhang C; Zhang S; Zhu J; Li X; Su P; Zhuang T
Oncogene; 2024 Jan; 43(4):248-264. PubMed ID: 38017133
[TBL] [Abstract][Full Text] [Related]
2. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway.
Seo D; Jung SM; Park JS; Lee J; Ha J; Kim M; Park SH
EBioMedicine; 2019 Nov; 49():55-71. PubMed ID: 31685442
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma.
Zhu R; Liu Y; Zhou H; Li L; Li Y; Ding F; Cao X; Liu Z
Cancer Lett; 2018 Apr; 418():125-134. PubMed ID: 29331416
[TBL] [Abstract][Full Text] [Related]
5. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
6. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
7. The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression.
Xia X; Huang C; Liao Y; Liu Y; He J; Shao Z; Hu T; Yu C; Jiang L; Liu J; Huang H
Cell Death Dis; 2021 Mar; 12(4):329. PubMed ID: 33771975
[TBL] [Abstract][Full Text] [Related]
8. circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells.
Li Z; Li Y; Han D; Wang X; Li C; Chen T; Li W; Liang Y; Luo D; Chen B; Wang L; Zhao W; Yang Q
Cell Death Dis; 2023 Jul; 14(7):482. PubMed ID: 37524698
[TBL] [Abstract][Full Text] [Related]
9. Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination.
Panno ML; Giordano F; Rizza P; Pellegrino M; Zito D; Giordano C; Mauro L; Catalano S; Aquila S; Sisci D; De Amicis F; Vivacqua A; Fuqua SW; Andò S
Breast Cancer Res Treat; 2012 Nov; 136(2):443-55. PubMed ID: 23053665
[TBL] [Abstract][Full Text] [Related]
10. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
[TBL] [Abstract][Full Text] [Related]
12. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
13. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.
He L; Yu C; Qin S; Zheng E; Liu X; Liu Y; Yu S; Liu Y; Dou X; Shang Z; Wang Y; Wang Y; Zhou X; Liu B; Zhong Y; Liu Z; Lu J; Sun L
Mol Cell; 2023 Nov; 83(22):4000-4016.e6. PubMed ID: 37935198
[TBL] [Abstract][Full Text] [Related]
14. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
15. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
[TBL] [Abstract][Full Text] [Related]
16. MINDY1 promotes breast cancer cell proliferation by stabilizing estrogen receptor α.
Tang J; Luo Y; Long G; Zhou L
Cell Death Dis; 2021 Oct; 12(10):937. PubMed ID: 34645792
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
Lv J; Zhang S; Wu H; Lu J; Lu Y; Wang F; Zhao W; Zhan P; Lu J; Fang Q; Xie C; Yin Z
Cancer Lett; 2020 Jan; 469():22-34. PubMed ID: 31634528
[TBL] [Abstract][Full Text] [Related]
18. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract][Full Text] [Related]
19. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
20. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
